Wedbush Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX)

Analysts at Wedbush began coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note issued to investors on Thursday, Marketbeat reports. The brokerage set an “outperform” rating and a $31.00 price target on the stock. Wedbush’s price objective points to a potential upside of 155.56% from the company’s previous close.

Several other research firms also recently commented on BCAX. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective on the stock. HC Wainwright increased their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Bicara Therapeutics has a consensus rating of “Buy” and a consensus price target of $41.20.

Bicara Therapeutics Stock Down 3.7 %

Shares of BCAX opened at $12.13 on Thursday. The company has a 50-day moving average price of $15.84. Bicara Therapeutics has a one year low of $11.10 and a one year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, research analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. bought a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at $177,169,000. FMR LLC acquired a new position in Bicara Therapeutics in the third quarter valued at about $57,913,000. Braidwell LP bought a new stake in Bicara Therapeutics during the third quarter worth about $42,219,000. Janus Henderson Group PLC acquired a new stake in Bicara Therapeutics during the third quarter worth about $30,329,000. Finally, Baker BROS. Advisors LP bought a new position in Bicara Therapeutics in the 3rd quarter valued at about $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.